Journal of Drug Abuse Open Access

  • ISSN: 2471-853X
  • Journal h-index: 10
  • Journal CiteScore: 1.81
  • Journal Impact Factor: 1.92
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Commentary - (2019) Volume 5, Issue 1

Analyses of the Public Health Impact of Cannabis Must Include the Health Benefits of Moderate Use

Thomas M Clark*

Department of Biological Sciences, Indiana University South Bend, USA

*Corresponding Author:

Thomas M Clark
Department of Biological Sciences
Indiana University South Bend, USA
Tel: 574-520-4882

Received Date: March 19, 2019; Accepted Date: March 30, 2019; Published Date: April 07, 2019

Citation: Clark TM (2019) Analyses of the Public Health Impact of Cannabis Must Include the Health Benefits of Moderate Use. J Drug Abuse Vol.5 No.1:3

Visit for more related articles at Journal of Drug Abuse


The current discussion of the public health impact of Cannabis use fails to consider the beneficial effects of moderate, adult use, resulting in a misleading perception of harm. Cannabis use counteracts two serious public health crises, the obesity epidemic and the drug overdose epidemic, thereby providing a net improvement in public health.

Of greatest significance from a public health perspective, Cannabis use counteracts the metabolic damage caused by the modern American diet. This diet is obesogenic and proinflammatory, and contributes strongly to leading causes of death. Obesity rates are spiking, having increased more than threefold since the early 1960s. The state with the lowest obesity rate, Colorado, now has a rate of obesity (20%) that is double the national average in 1960 (10%) (data from CDC). Diseases associated with obesity include cancer, cardiovascular disease, diabetes mellitus, Alzheimer’s disease, mood disorders, liver and kidney disease, and musculoskeletal disorders. These include the leading causes of premature death and disability in the United States. Of particular concern, rates of these diseases are rising in young adults, reducing life expectancy and quality of life for a large proportion of the population. Cannabis users show significantly decreased rates of obesity and improved metabolic profiles [1-4].

A well-supported, comprehensive theory has been established that details how Cannabis use improves metabolic function by reversing the harm caused by the modern industrial diet [1]. Human physiology has not changed since 1960, but our food supply has changed a great deal. One of the most significant of these changes is a shift in the ratio of two essential nutrients, the omega-6 and omega-3 fatty acids. Prior to the emergence of industrial, processed food as a major component of our diet, the dietary ratio of omega-6 to omega-3 fatty acids was approximately 4:1. In the modern diet of processed foods, this ratio has increased to as much as 20:1 [5]. This shift leads to overstimulation of the endocannabinoid system, the internal signaling system acted upon by the active chemicals of Cannabis.

The endocannabinoid system consists of signaling molecules and receptors. The main signals are AEA and 2-AG, and the main receptors are CB1R and CB2R. AEA and 2-AG are synthesized from arachidonic acid, an omega-6 fatty acid. These signals are elevated in obesity due to an elevated ratio of omega-6 to omega-3 fatty acids in the diet, resulting in chronic overstimulation of the receptors [6,7]. Of especial concern in the obesity epidemic is overstimulation of CB1R. This receptor’s primary function is to stimulate weight gain. When stimulated, it increases appetite, palatability of food, absorption of food, and assimilation of energy reserves. At the same time, it promotes conservation of energy by reducing the metabolic rate [8]. In the context of abundant, calorie rich food and a sedentary lifestyle, overstimulation of this system is the perfect recipe for obesity and associated diseases such as DM [9].

The CB1R receptor is also stimulated by THC, the main psychoactive compound in Cannabis. In the short term, this causes the increased appetite, hyperphagia and hypothermia associated with the acute stages of Cannabis use. Despite significant increases in daily caloric intake, however, Cannabis users have clinically significant decreases in obesity rates relative to non-users. A well-supported theoretical explanation for this paradox has recently been established [1]. According to this theory, Cannabis use causes a rapid and long-lasting downregulation of CB1R, reducing the sensitivity of the endocannabinoid system. Because CB1R is overstimulated due to elevated production of AEA and 2-AG, caused by the elevated omega-6 to omega-3 ratio of the diet, downregulation of the receptor acts to bring the system back into homeostasis [1]. Multiple studies have shown lower rates of DM in Cannabis users [2,10], as well as improved metabolic profiles [3]. Cannabinoids provide significant benefits in Alzheimer’s disease, potentially reversing the progression of the disease [11]. In addition to reducing obesity rates, and thus rates of cancers associated with obesity, cannabinoids have potent anti-tumor properties, reducing tumor initiation, spread, and survival [12]. Cannabis users therefore appear to have lower rates of cancer than non-users [13]. Cannabis thus acts to reverse or prevent many of the harmful effects of the modern diet, currently the leading cause of premature death and disability in the United States [14].

In addition to the metabolic benefits from Cannabis use, legalization of medical marijuana is followed by decreases in prescriptions for multiple classes of pharmaceuticals, including drugs to treat depression, anxiety, pain, psychosis, spasticity, and insomnia. Reasons given by patients for substitution include improved symptom management, milder adverse side effects and withdrawal symptoms, and lower cost. Of especial importance is a decrease in use of opioids and benzodiazepines [15,16]. These are the main drugs involved in fatal overdoses [17] and legalization of medical marijuana is therefore followed by a substantial decrease in overdose death [18]. This is not accompanied by increased traffic fatalities [19].

Just as with exercise, we cannot focus on only the harmful effects but must consider also the beneficial effects of Cannabis when evaluating its public health impact. Heavy Cannabis use, or use by susceptible individuals, is associated with negative outcomes, especially in adolescents. However, medical use, and moderate recreational use by adults, appears to be associated with significant health benefits in the context of the modern industrial diet, and can thus contribute to a healthy lifestyle. Cannabis not only improves the quality of life of many people, it also prevents many premature deaths [15,17,18,20]. When these health benefits are considered, it becomes clear that prohibition is a greater threat to public health than Cannabis [13,21].


  1. Clark TM, Jones JM, Hall AG, Tabner SA, Kmiec RL (2018) Theoretical explanation for reduced body mass index and obesity rates in cannabis users. Cannabis Cannabinoid Res 3: 259-271.
  2. Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, et al. (2012) Decreased prevalence of diabetes in marijuana users: Cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. BMJ Open 2: e000494.
  3. Penner EA, Buettner H, Mittleman MA (2013) The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am J Med 126: 583-589.
  4. Vázquez-Bourgon J, Setién-Suero E, Pilar-Cuéllar F, Romero-Jiménez R, Ortiz-García de la Foz V, et al. (2019) Effect of Cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study. J Psychopharmacol 33: 284-294.
  5. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR (2011) Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. The Am J Clin Nutr 93: 950-962.
  6. Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH (2018) Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 21: 695-714.
  7. Bisogno T, Maccarrone M (2014) Endocannabinoid signaling and its regulation by nutrients. Biofactors 40: 373-380.
  8. Mazier W, Saucisse N, Gatta-Cherifi B, Cota D (2015) The endocannabinoid system: Pivotal orchestrator of obesity and metabolic disease. Trends Endocrinol Metab 26: 524-537.
  9. Gruden G, Barutta F, Kunos G2, Pacher P (2016) Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol 173: 1116-1127.
  10. Alshaarawy O, Anthony JC (2015) Cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replication samples. Epidemiology 26: 597.
  11. Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S (2015) The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. J Alzheimers Dis 43: 1115-1136.
  12. Velasco G, Sánchez C, Guzmán M (2012) Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 12: 436-444.
  13. Clark TM (2017) Cannabis use substantially reduces the premature death rate in the United States. Indiana University South Bend.
  14. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, et al. (2013) The state of US health, 1990-2010: Burden of diseases, injuries, and risk factors. JAMA 310: 591-606.
  15. Bradford AC, Bradford WD (2016) Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Millwood) 35: 1230-1236.
  16. Purcell C, Davis A, Moolman N, Taylor SM (2018) Reduction of benzodiazepine use in patients prescribed medical cannabis. Cannabis Cannabinoid Res.
  17. Jones CM, Mack KA, Paulozzi LJ (2013) Pharmaceutical overdose deaths, United States, 2010. JAMA 309: 657-659.
  18. Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014). Medical Cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 174: 1668-1673.
  19. Santaella-Tenorio J, Mauro CM, Wall MM, Kim JH, Cerdá M (2017) US traffic fatalities, 1985-2014, and their relationship to medical marijuana laws. Am J Public Health 107: 336-342.
  20. Boehnke KF, Litinas E, Clauw DJ (2016) Medical Cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17: 739-744.
  21. Nathan DL, Clark HW, Elders J (2017) The physicians' case for marijuana legalization. Am J Public Health 107: 1746-1747.